Leaders in Pharmaceutical Business Intelligence (LPBI) Group

Personalized medicine is turning a corner. FDA approved four new indications for personalized medicine in July of 2015, a record for the agency and the field. As you may remember, 20 percent of FDA’s 2014 drug approvals were personalized medicines. At this rate, that percentage will likely be matched or exceeded this year.

But what does that mean for the field?

It means policymakers throughout the health care ecosystem have to play catch up, because ethically and scientifically there is no going back. Science has led us here because personalized medicines save and extend lives. They keep people at work, enjoying their families and contributing to society. They reduce morbidity and the adverse health events associated with older treatments. And for some patients they extend lives long enough to allow for participation in promising clinical trials, which can extend lives even further.

For evidence of personalized medicine’s potential, look no…